[go: up one dir, main page]

JP2004043490A - Nutrient infusion - Google Patents

Nutrient infusion Download PDF

Info

Publication number
JP2004043490A
JP2004043490A JP2003302385A JP2003302385A JP2004043490A JP 2004043490 A JP2004043490 A JP 2004043490A JP 2003302385 A JP2003302385 A JP 2003302385A JP 2003302385 A JP2003302385 A JP 2003302385A JP 2004043490 A JP2004043490 A JP 2004043490A
Authority
JP
Japan
Prior art keywords
infusion
trehalose
glucide
nutrient infusion
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003302385A
Other languages
Japanese (ja)
Inventor
Yukifumi Kuniba
國場 幸史
Kanji Arii
有井 幹治
Ichiro Makita
牧田 市郎
Shunzo Yamashita
山下 俊三
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Ajinomoto Pharmaceuticals Co Ltd
Original Assignee
Ajinomoto Co Inc
Ajinomoto Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc, Ajinomoto Pharma Co Ltd filed Critical Ajinomoto Co Inc
Priority to JP2003302385A priority Critical patent/JP2004043490A/en
Publication of JP2004043490A publication Critical patent/JP2004043490A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a nutrient infusion excellent in both stability in an aqueous state and availability in an organism and containing a glucide with high safety as well. <P>SOLUTION: This nutrient infusion contains trehalose as a glucide calorie source and is subjected to high-pressure steam sterilization. Accordingly, the glucide is highly concentrated when necessary, and is so controlled as to have a pH of 5.5 or higher. Therefore, the extremely useful nutrient infusion which is used as a basic solution for hyperalimentary liquid administered through a central vein or as a medium calorie infusion administered through a peripheral vein is provided. <P>COPYRIGHT: (C)2004,JPO

Description

 本発明は、トレハロースを含有し、かつ、高圧蒸気滅菌された栄養輸液剤に関する。 The present invention relates to a nutritional infusion containing trehalose and sterilized by autoclaving.

 従来より、栄養輸液剤の糖質カロリー源として、グルコース、フルクトース、マルトース、ソルビトール、キシリトール等が用いられている。 グ ル コ ー ス Conventionally, glucose, fructose, maltose, sorbitol, xylitol and the like have been used as a source of carbohydrate calories in nutritional infusions.

 しかし、これらの糖質は、水溶液状態での安定性、生体での利用率あるいは安全性の面から、必ずしも満足なものとは言えない。 However, these saccharides are not always satisfactory in terms of stability in an aqueous solution state, availability in a living body, or safety.

 例えば、グルコースは、水溶液のpHを5.5以上にすると分解し易くなるという問題がある。したがって、グルコース含有輸液剤のpHは、通常5.5以下に調整されているが、このような非生理的な酸性溶液を末梢静脈から投与すると、静脈炎を惹起する危険性がある(Fonkalsrud E. W. et al., J. Surg. Res., 8, 539 (1968))。フルクトースは、血中乳酸の上昇を招いてアシドーシスを誘発することがある(伊藤宗元ら編、「医薬品の副作用」、中外医学社、東京、1991、P.83)。マルトース、ソルビトールおよびキシリトールは、通常の速度で経静脈投与すると、かなりの部分が利用されないまま尿中に排泄されるという問題がある(松崎舜二、薬物療法、,295(1973))。また、グルコース等の単糖類の場合、一定量の輸液剤投与でカロリー量を増加させたいとき、上げ得る濃度の範囲は、浸透圧の問題から、二糖類で可能な濃度の約2分の1までという制約がある。
Fonkalsrud E. W. et al., J. Surg. Res., 8, 539 (1968) 伊藤宗元ら編、「医薬品の副作用」、中外医学社、東京、1991、P.83 松崎舜二、薬物療法、6,295(1973)
For example, glucose has a problem that it is easily decomposed when the pH of an aqueous solution is 5.5 or more. Therefore, the pH of a glucose-containing infusion is usually adjusted to 5.5 or less, but administration of such a non-physiological acidic solution from a peripheral vein may cause phlebitis (Fonkalsrud EW). et al., J. Surg. Res., 8 , 539 (1968)). Fructose may induce acidosis by inducing an increase in blood lactic acid (edited by Munemoto Ito et al., “Side Effects of Drugs”, Chugai Medical, Tokyo, 1991, p. 83). Maltose, sorbitol and xylitol have a problem in that when administered intravenously at a normal rate, a significant part of the maltose, sorbitol and xylitol are excreted in the urine without much use (Shunji Matsuzaki, Pharmaceutical Therapy, 6 , 295 (1973)). In addition, in the case of monosaccharides such as glucose, when it is desired to increase the amount of calories by administering a certain amount of an infusion solution, the range of the concentration that can be increased is about one-half the concentration possible with the disaccharide due to the problem of osmotic pressure. There is a restriction of up to.
Fonkalsrud EW et al., J. Surg. Res., 8, 539 (1968) Edited by M. Ito et al., "Side Effects of Pharmaceuticals," Chugai Medical Company, Tokyo, 1991, p. 83 Matsuzaki Shunji, Pharmacotherapy, 6,295 (1973)

 本発明の課題は、水溶液状態での安定性と生体での利用率がともに優れ、しかも安全性の高い糖質を含有する栄養輸液剤を提供することである。 課題 An object of the present invention is to provide a nutrient infusion containing a carbohydrate which is excellent in both stability in an aqueous solution state and utilization rate in a living body and is highly safe.

 本発明者らは、栄養輸液剤のカロリー源として未だ使用されていない種々の糖質を用いて、前記背景技術の各問題点につき検討した。その結果、二糖類であるトレハロースを用いることによって、上記課題を解決できることを見出し、本発明を完成するに至った。 The present inventors have examined various problems of the background art using various carbohydrates that have not been used as a calorie source of a nutritional infusion. As a result, they have found that the above problem can be solved by using trehalose, which is a disaccharide, and have completed the present invention.

 すなわち、本発明は、糖質カロリー源としてトレハロースを含有し、かつ、高圧蒸気滅菌されたことを特徴とする栄養輸液剤を提供するものである。 That is, the present invention provides a nutrient infusion containing trehalose as a carbohydrate source and being subjected to high-pressure steam sterilization.

 本発明に係るトレハロースには、α,α−トレハロース、α,β−トレハロース又はβ,β−トレハロースの3種が存在するが、より好ましくは天然に存在するα,α−トレハロースである。 ト レ The trehalose according to the present invention includes three kinds of α, α-trehalose, α, β-trehalose, and β, β-trehalose, and is more preferably naturally occurring α, α-trehalose.

 本発明の栄養輸液剤は、トレハロースのほか、電解質、ビタミン類等必要な栄養素を含ませることができる。例えば、好ましい製剤として、1000ml中、10〜500gのトレハロースと共に、第1表に示す電解質に含まれる元素を同表に示す濃度範囲内で1種又は2種以上配合したものを挙げることができる。 The nutrient infusion of the present invention can contain necessary nutrients such as electrolytes and vitamins in addition to trehalose. For example, as a preferred preparation, one or more of the elements contained in the electrolytes shown in Table 1 in the concentration range shown in Table 1 can be used together with 10 to 500 g of trehalose in 1000 ml.

Figure 2004043490
Figure 2004043490

 前記元素を含む電解質としては、水酸化ナトリウム、塩化ナトリウム、酢酸ナトリウム、乳酸ナトリウム、クエン酸ナトリウム、塩化カリウム、乳酸カリウム、クエン酸カリウム、酢酸カルシウム、乳酸カルシウム、グルコン酸カルシウム、パントテン酸カルシウム、硫酸マグネシウム、リン酸一水素ナトリウム、リン酸一水素カリウム、リン酸二水素ナトリウム、リン酸二水素カリウム、塩酸、硫酸亜鉛、塩化亜鉛、硫酸鉄、塩化第一鉄、塩化第二鉄、硫酸銅、ヨウ化ナトリウム、ヨウ化カリウム、硫酸マンガン等が挙げられる。 Examples of the electrolyte containing the element include sodium hydroxide, sodium chloride, sodium acetate, sodium lactate, sodium citrate, potassium chloride, potassium lactate, potassium citrate, calcium acetate, calcium lactate, calcium gluconate, calcium pantothenate, and sulfuric acid. Magnesium, sodium monohydrogen phosphate, potassium monohydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, hydrochloric acid, zinc sulfate, zinc chloride, iron sulfate, ferrous chloride, ferric chloride, copper sulfate, Examples thereof include sodium iodide, potassium iodide, and manganese sulfate.

 本発明の栄養輸液剤は、高圧蒸気滅菌によって容易に製造できる。 The nutritional infusion of the present invention can be easily produced by autoclaving.

 α,α−トレハロース100gを蒸留水に溶解して全量を1000mlとした。この溶液を孔径0.22μmのメンブランフィルターで濾過し、200mlのガラス瓶に充填し、空間部を窒素ガスで置換後密栓した。これを常法に従って高圧蒸気滅菌して栄養輸液剤を得た。 100 g of α, α-trehalose was dissolved in distilled water to make the total volume 1000 ml. This solution was filtered through a membrane filter having a pore size of 0.22 μm, filled in a 200-ml glass bottle, and the space was replaced with nitrogen gas and sealed. This was subjected to high-pressure steam sterilization according to a conventional method to obtain a nutritional infusion.

 α,α−トレハロース500gを蒸留水に溶解して950mlとし、1規定の水酸化ナトリウム水溶液でpHを7.0に調整した後、全量を1000mlとした。以下、実施例1と同様にして栄養輸液剤を得た。 500 g of αα, α-trehalose was dissolved in distilled water to make 950 ml, the pH was adjusted to 7.0 with a 1N aqueous sodium hydroxide solution, and the total amount was made 1000 ml. Thereafter, a nutritional infusion was obtained in the same manner as in Example 1.

 下記第2表に示す組成物を蒸留水に溶解して950mlとし、1規定の塩酸でpHを5.0に調整した後、全量を1000mlとした。以下、実施例1と同様にして栄養輸液剤を得た。 (4) The compositions shown in Table 2 below were dissolved in distilled water to make 950 ml, the pH was adjusted to 5.0 with 1N hydrochloric acid, and the total amount was made to 1000 ml. Thereafter, a nutritional infusion was obtained in the same manner as in Example 1.

Figure 2004043490
Figure 2004043490

 実施例3の工程中、1規定の水酸化ナトリウム水溶液でpHを6.0に調整した以外は実施例3と同様にして栄養輸液剤を得た。 栄 養 A nutrient infusion was obtained in the same manner as in Example 3, except that the pH was adjusted to 6.0 with a 1N aqueous sodium hydroxide solution in the process of Example 3.

 実施例3の工程中、1規定の水酸化ナトリウム水溶液でpHを7.0に調整した以外は実施例3と同様にして栄養輸液剤を得た。 栄 養 A nutrient infusion was obtained in the same manner as in Example 3 except that the pH was adjusted to 7.0 with a 1N aqueous sodium hydroxide solution in the process of Example 3.

 下記第3表に示す組成物を蒸留水に溶解して950mlとし、1規定の水酸化ナトリウム水溶液でpHを7.0に調整した後、全量を1000mlとした。以下、実施例1と同様にして栄養輸液剤を得た。 (4) The compositions shown in Table 3 below were dissolved in distilled water to make 950 ml, the pH was adjusted to 7.0 with a 1N aqueous sodium hydroxide solution, and the total amount was made to 1000 ml. Thereafter, a nutritional infusion was obtained in the same manner as in Example 1.

Figure 2004043490
Figure 2004043490

 下記第4表に示す組成物を蒸留水に溶解して950mlとし、1規定の水酸化ナトリウム水溶液でpHを7.0に調整した後、全量を1000mlとした。以下、実施例1と同様にして栄養輸液剤を得た。 (4) The compositions shown in Table 4 below were dissolved in distilled water to make 950 ml, the pH was adjusted to 7.0 with a 1N aqueous sodium hydroxide solution, and the total amount was made to 1000 ml. Thereafter, a nutritional infusion was obtained in the same manner as in Example 1.

Figure 2004043490
Figure 2004043490

 以下に記載する試験例で実施例1〜7の栄養輸液剤と共に用いた対照液1〜10(下記第5表)は、実施例1の方法に準拠して調製した。 対 照 Control solutions 1 to 10 (Table 5 below) used together with the nutritional infusions of Examples 1 to 7 in the test examples described below were prepared according to the method of Example 1.

Figure 2004043490
Figure 2004043490

試験例1Test example 1

 体重2.0〜2.5kgの日本白色種雄性ウサギ(1群4羽)を固定器に入れ、耳介静脈より実施例1の栄養輸液剤、対照液1及び2の各被験液を5ml/kg/hrの速度で4時間持続投与した。投与終了後、ウサギを個別代謝ケージに移し、24時間尿を採取した。なお、実験期間中は絶食、絶水とした。採取した尿中の糖を測定し、その排泄率を算出した。その結果(下記第6表)、α,α−トレハロースは、グルコースと同様、生体での利用率が良い糖質であることが判明した。 A Japanese white male rabbit (4 birds per group) weighing 2.0 to 2.5 kg was placed in a fixing device, and the nutrient infusion of Example 1 and each of the test solutions of Control Solutions 1 and 2 were injected through the auricular vein at 5 ml / vol. The administration was continued for 4 hours at a rate of kg / hr. After the administration, the rabbits were transferred to individual metabolic cages, and urine was collected for 24 hours. During the experimental period, the animals were fasted and watered. The sugar in the collected urine was measured, and the excretion rate was calculated. As a result (Table 6 below), α, α-trehalose was found to be a carbohydrate having a good utilization rate in a living body, similarly to glucose.

Figure 2004043490
Figure 2004043490

試験例2Test example 2

 実施例2の栄養輸液剤及び対照液3につき、生理食塩水を標準として浸透圧比を測定した。 に つ き The osmotic pressure ratio of the nutritional infusion solution of Example 2 and the control solution 3 was measured using physiological saline as a standard.

 次に、105℃で90分間高圧蒸気滅菌した後、着色度の指標として波長430nmの光の透過率を測定した。さらに、前記滅菌後の各液を蒸留水で10倍に希釈し、糖質分解の指標として波長284nmの吸光度を測定した。 Next, after high-pressure steam sterilization at 105 ° C. for 90 minutes, the transmittance of light having a wavelength of 430 nm was measured as an index of the degree of coloring. Further, each liquid after the sterilization was diluted 10 times with distilled water, and the absorbance at a wavelength of 284 nm was measured as an index of carbohydrate decomposition.

 これらの測定結果(下記第7表)から、α,α−トレハロースは、グルコースより糖質の高濃度化に有利であり、pH7.0で極めて安定であることが分かる。 か ら From the results of these measurements (Table 7 below), it can be seen that α, α-trehalose is more advantageous for increasing the concentration of carbohydrates than glucose and is extremely stable at pH 7.0.

Figure 2004043490
Figure 2004043490

試験例3Test example 3

 実施例3〜7の栄養輸液剤及び対照液4〜10の各液につき、105℃で90分間高圧蒸気滅菌した後、波長284nmの吸光度と波長430nm光の透過率を測定した。なお、実施例6の栄養輸液剤及び対照液10の各吸光度は、蒸留水で6倍に希釈し測定した。その結果(下記第8表)、pH5.0〜7.0でα,α−トレハロースが最も安定性に優れていることが判明した。 栄 養 Each of the nutritional infusions of Examples 3 to 7 and the control solutions 4 to 10 was subjected to high-pressure steam sterilization at 105 ° C. for 90 minutes, and then the absorbance at a wavelength of 284 nm and the transmittance of light at a wavelength of 430 nm were measured. In addition, each absorbance of the nutrient infusion solution of Example 6 and the control solution 10 was diluted 6 times with distilled water and measured. As a result (Table 8 below), it was found that α, α-trehalose was most excellent in stability at pH 5.0 to 7.0.

Figure 2004043490
Figure 2004043490

 体重230〜260gのSD系ラット(5匹)に、実施例2の栄養輸液剤10ml/kg(5g/kg)を尾静脈から急速投与した。その結果、死亡例は認められず、特記すべき一般症状も観察されなかった。 SD 10 ml / kg (5 g / kg) of the nutritional infusion of Example 2 was rapidly administered to the SD rats (5 rats) weighing 230 to 260 g from the tail vein. As a result, no deaths were observed and no notable general symptoms were observed.

 トレハロースは、水溶液のpHが7前後でも十分安定な二糖類であり、生体での利用率がよく、しかも安全性が高い。したがって、本発明によれば、必要に応じて糖質の高濃度化が図れ、pHを5.5以上に調整できることから、中心静脈から投与する高カロリー輸液の基本液として、あるいは末梢静脈から投与する中カロリー輸液剤として、極めて有用な栄養輸液剤を提供することができる。 @ Trehalose is a disaccharide that is sufficiently stable even when the pH of the aqueous solution is around 7, has a high availability in living organisms, and has high safety. Therefore, according to the present invention, the concentration of carbohydrates can be increased as necessary, and the pH can be adjusted to 5.5 or more. An extremely useful nutritional infusion can be provided as a medium-calorie infusion.

Claims (3)

 糖質カロリー源としてトレハロースを含有し、かつ、高圧蒸気滅菌されたことを特徴とする栄養輸液剤。 (4) A nutritional infusion containing trehalose as a carbohydrate calorie source and being autoclaved.  該高圧蒸気滅菌後の430nm光の透過率が99.7%以上であることを特徴とする請求項1記載の栄養輸液剤。 (4) The nutritional infusion according to (1), wherein the transmittance of 430 nm light after the high-pressure steam sterilization is 99.7% or more.  該トレハロースがα、α−トレハロースまたはβ,β−トレハロースであることを特徴とする請求項1または2記載の栄養輸液剤。 (3) The nutritional infusion according to (1) or (2), wherein the trehalose is α, α-trehalose or β, β-trehalose.
JP2003302385A 1992-07-10 2003-08-27 Nutrient infusion Pending JP2004043490A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003302385A JP2004043490A (en) 1992-07-10 2003-08-27 Nutrient infusion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20716192 1992-07-10
JP2003302385A JP2004043490A (en) 1992-07-10 2003-08-27 Nutrient infusion

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP31394992A Division JP3572085B2 (en) 1992-07-10 1992-10-28 Nutritional infusion

Publications (1)

Publication Number Publication Date
JP2004043490A true JP2004043490A (en) 2004-02-12

Family

ID=31719110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003302385A Pending JP2004043490A (en) 1992-07-10 2003-08-27 Nutrient infusion

Country Status (1)

Country Link
JP (1) JP2004043490A (en)

Similar Documents

Publication Publication Date Title
AP1185A (en) Novel pharmaceutical composition for the use in emergency treatment and preparation method thereof.
DE3812525C1 (en)
US5534509A (en) Pharmaceutical composition regulating function of a living body
EP0078832A1 (en) Dialysis solution containing glycerol.
Abukurah et al. Acute sodium fluoride poisoning
JP2012140468A (en) Peritoneal dialysis fluid
Lebowitz et al. The pH and acidity of intravenous infusion solutions
JP3572085B2 (en) Nutritional infusion
JP2004043490A (en) Nutrient infusion
Ussing et al. The effect of glucose on cation transport
Lopez et al. Survival of a child despite unusually high blood ethanol levels
DE69527205T2 (en) MEDICINE AGAINST ENDOTOXIN SHOCK AND MULTIPLE ORGAN FAILURE THAT CAUSED
Beigelman et al. Severe diabetic ketoacidosis
Macaulay Hyperosmolar non-ketotic diabetes
JP2720165B2 (en) Glucose electrolyte compounding agent
EP0799048B1 (en) Body fluid replacement solution
Hoffman et al. Anamp'by any other name: the hazards of intravenous magnesium dosing
PARTENHEIMER et al. PRACTICAL CONTROL OF FLUID AND ELECTROLYTE BALANCE IN CARBON TETRACHLORIDE NEPHROSIS: Report of Cases
JP2002282354A (en) Peritoneal dialysate
JPH1149671A (en) Peritoneal dialysate
JP3643879B2 (en) Electrolyte infusion composition
Stroh Alcoholic Student on a Beer and Vomiting Binge
SU686734A1 (en) Remedy for treatment of pneumonia, anemia and dyspepsia
Peters Some remarks on diabetic acidosis
JPS6354691B2 (en)

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Effective date: 20050628

Free format text: JAPANESE INTERMEDIATE CODE: A712

RD04 Notification of resignation of power of attorney

Effective date: 20060202

Free format text: JAPANESE INTERMEDIATE CODE: A7424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070426

A521 Written amendment

Effective date: 20070625

Free format text: JAPANESE INTERMEDIATE CODE: A523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070921